Announcements Trials
Browse Landscape

Phase

Phase 2 16Phase 1 13Phase 3 5Phase 2/3 3Phase NA 1

Status

Not yet recruiting 3Recruiting 1Completed 1

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 260Lymphoid 13Tumor-Agnostic 5Gynecologic 3Thoracic 1Sarcoma 1Other solid neoplasm 1NET 1Genitourinary 1Endocrine 1

Conditions

Neoplasms 3Adenocarcinoma 3Neoplasm Metastasis 1

Interventions

Carboplatin 8Paclitaxel 7Fluorouracil 7Cisplatin 7atezolizumab 5Trastuzumab 5Pemetrexed 5Oxaliplatin 5Leucovorin 5Bevacizumab 5pembrolizumab 4Gemcitabine 4Capecitabine 4Albumin-Bound Paclitaxel 4Surveys and Questionnaires 3Observation 3Leuprolide 3Irinotecan 3Glutamine 3Drug Therapy 3Docetaxel 3Dexamethasone 3130-nm albumin-bound paclitaxel 3trifluridine tipiracil drug combination 2regorafenib 2osimertinib 2enzalutamide 2Surgical Procedures, Operative 2Standard of Care 2Sorafenib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 3 × Oxaliplatin × Tumor-Agnostic × Clear all
NCT06901531 2026-06-05

LUCERNA

Astellas Pharma Inc

Phase 3 Recruiting
500 enrolled
Tumor-Agnostic

Adenocarcinoma, Neoplasms

NCT07385703 2026-02-04

Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 3 Not yet recruiting
752 enrolled
Tumor-Agnostic

Adenocarcinoma

NCT07118800 2025-08-12

NACRE-2

UNICANCER

Phase 3 Not yet recruiting
160 enrolled
Tumor-Agnostic

Adenocarcinoma

NCT02625610 2022-06-09

Avelumab in First-Line Maintenance Gastric Cancer (JAVELIN Gastric 100)

EMD Serono

Phase 3 Completed
499 enrolled 22 charts
Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

NCT03961841 2019-12-23

Perioperative Combination Chemotherapy Versus Chemoradiation for Locally Advanced EGJ Adenocarcinoma

Sixth Affiliated Hospital, Sun Yat-sen University

Phase 3 Not yet recruiting
900 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡